



RECORDED AND INDEXED  
RESPONSE UNDER 37 C.F.R. §1.116  
SEARCHED, SERIALIZED, FILED  
EXAMINING ATTORNEY GROUP 1803

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Christine L. Brakel et al.

Serial No.: 07/446,235 Group Art Unit: 1803

Filed: December 4, 1989 Examiner: Gary L. Kunz, Ph.D

For: **MODIFIED NUCLEOTIDE COMPOUNDS**

Honorable Commissioner of  
Patents and Trademark  
Washington, D.C. 20231

**ATTENTION: BOX AF**

SEP 14 1993  
SAC

Sir:

Transmitted herewith is a response (Response Under 37 C.F.R. §1.116) in the above-identified patent application.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	51	Minus	51	= 0	x 11	\$ 0
Indep	7	Minus	7	= 0	x 37	\$ 0
( ) First Presentation of Multiple Dependent Claims					+ 115	\$ 0
TOTAL ADDITIONAL FEE -----					-----	\$ 0

( ) Charge Deposit Account No. 05-1135 in the amount of \$ \_\_\_\_.

( ) A check in the amount of \$ \_\_\_\_\_ is attached.

(X) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135: any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. §1.17.

Copies are being provided in triplicate.

Respectfully submitted,

Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicant(s)

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.

575 Fifth Avenue (18th Floor)  
New York, New York 10017  
Tel. (212) 856-0876

Attorney's Docket No.: **Enz-47**

**FIRST CLASS CERTIFICATE**

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks Washington, D.C. 20231

Ronald C. Fedus  
Reg. No. 32,567

SEPTEMBER 3, 1993  
Date